Spotlight On
β Transformation occurs in a minority of patients, with an extremely poor prognosis
Latest in Spotlight On
"It is really a discussion of their individual health conditions," one expert says
Two new drugs offer promise after obeticholic acid misses out on full approval
Disease chronicity and progression raise ongoing questions
More research needed on role of local therapy in new era of treatment
Disease chronicity and progression raise ongoing questions
More research needed on role of local therapy in new era of treatment
More in Spotlight On
Balancing risk and benefit takes a personal approach with frailty scores, clinical assessments
Expert insights into clinical progress and future perspectives
New research focuses on interventions for highest-risk patients
Though only one approved agent has been available for decades, the armamentarium has expanded
A major reason for the increase in prevalence is increased survival from improved management
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
Delayed diagnosis may affect patients in multiple ways
Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets
Momentum grows for earlier intervention, including pre-fibrotic disease
The approval of lazertinib/amivantamab gives clinicians one more option
TKIs are the first-line of defense, but "the more options we have the better," expert says
Got COVID from a sick family member? Maybe not, studies show
